ADVANCED NON-SMALL CELL LUNG CANCER

This study tests whether combining immunotherapy drugs can shrink tumors in people with advanced non-small cell lung cancer. About 400 adults with stage IV cancer will receive these combinations. The main goals are to see how many patients respond and to check for side effects.

This study tests a new drug, BAY 2927088, for people with advanced non-small cell lung cancer that has specific changes (mutations) in the EGFR or HER2 genes. The drug aims to block these abnormal proteins to stop cancer growth. The trial involves about 370 participants and will …

This study tests a new drug called DS-1062a in about 100 people with advanced non-small cell lung cancer that has spread or cannot be removed by surgery. Participants must have already tried at least one but no more than three standard treatments. The drug is given every three we…

This study tests two immunotherapy drugs (AK112 and AK104) together, with or without chemotherapy, in people with advanced non-small cell lung cancer that cannot be surgically removed. The goal is to see if this combination is safe and helps shrink tumors or slow the disease. Abo…

This early-stage study tests a drug called furmonertinib in 160 people with advanced lung cancer that has certain gene mutations (EGFR or HER2). The goal is to see if the drug is safe and can shrink tumors. Participants have already tried other treatments without success.

This study tests whether combining the targeted drug AZD9291 with either AZD6094 or selumetinib is safe and can shrink tumors in people with advanced EGFR-mutant non-small cell lung cancer that has worsened after prior targeted therapy. About 344 adults whose cancer has a specifi…

This study tests whether adding an experimental drug, BNT116, to the standard immunotherapy cemiplimab works better than cemiplimab alone for people with advanced non-small cell lung cancer. About 51 participants with a specific tumor marker (PD-L1 ≥50%) will receive either the c…

This phase 3 trial tests whether a new drug called AK112 works better than the standard immunotherapy pembrolizumab for people with advanced non-small cell lung cancer that has a specific marker (PD-L1). About 398 participants with stage IIIB/C or IV lung cancer will receive eith…

This trial was designed to test a combination of three drugs (SHR-A1921, adebrelimab, and SHR-8068) with or without chemotherapy for people with advanced non-small cell lung cancer. The goal was to see if the treatment was safe and shrank tumors. However, the study was withdrawn …

This study tests whether adding an experimental drug (fianlimab) to a standard immunotherapy (cemiplimab) works better than the standard drug alone for people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. About 850 participants will rece…

This study tests an experimental drug (FF-10832) given alone or with pembrolizumab (an immunotherapy) in about 120 adults with advanced lung or bladder cancer that has not responded to standard treatments. The main goals are to check safety and see how long the cancer can be kept…

This study examines the safety and effectiveness of a drug called cemiplimab combined with chemotherapy for people with advanced non-small cell lung cancer. Researchers will look at medical records from about 1,000 patients in the US to see how different groups (by age, sex, race…